title: Economics and cost-effectiveness in evaluating the value of cardiovascular therapies. Role of government agencies regarding cost-effectiveness claims: FDA perspective.
authors.affiliation: Center for Drugs Evaluation and Research, US Food and Drug Administration, Rockville, MD 20857, USA.
authors.forename: R
authors.initials: R
authors.lastname: Temple
mesh_terms: D002317:Cardiovascular Agents / Q000191:economics* / Q000627:therapeutic use*; D002318:Cardiovascular Diseases / Q000188:drug therapy* / Q000191:economics; D003362:Cost-Benefit Analysis / Q000331:legislation & jurisprudence*; D017277:Drug Approval / Q000191:economics / Q000331:legislation & jurisprudence*; D017850:Economics, Pharmaceutical; D006801:Humans; D014481:United States; D014486:United States Food and Drug Administration
chemical_list: D002317:Cardiovascular Agents